Dupixent^® Lawsuit

At Trustwell Law, our experienced attorneys take a personalized, compassionate approach. We cut through the legalese and partner with our clients. We also have access to the expertise, resources, and manpower to fully investigate each case and fight for and with our clients to get the justice they deserve.

What Is Dupixent and How Does It Relate to the Dupixent Lawsuit?

Dupixent (dupilumab) is a medication approved by the U.S. Food and Drug Administration (FDA) in 2017 to treat moderate to severe atopic dermatitis (eczema), asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis. Developed by Sanofi and Regeneron Pharmaceuticals, Dupixent works by blocking interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways to reduce type 2 inflammation. While Dupixent has proven to be effective for many, emerging evidence has sparked a wave of lawsuits alleging that the drug’s manufacturers failed to warn patients and physicians about a serious potential side effect: an increased risk of cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma that primarily affects the skin.

These Dupixent lawsuits claim that the absence of CTCL warnings on the drug’s label led to delayed diagnoses, as early symptoms of the cancer—such as persistent rashes, plaques, or itching—can mimic eczema flare-ups. Plaintiffs argue that this allowed the disease to progress unchecked, resulting in advanced-stage diagnoses, the need for more aggressive treatment and, in some cases, fatal outcomes. As of October 2025, the FDA’s Adverse Event Reporting System (FAERS) has logged nearly 300 reports of lymphoma linked to Dupixent, including over 138 cases of CTCL, prompting ongoing regulatory scrutiny but no label update or recall yet.

What Is Cutaneous T-Cell Lymphoma (CTCL)?

CTCL is a slow-growing cancer originating in T-cells, a type of white blood cell, that typically presents in the skin before potentially spreading to lymph nodes, blood, or internal organs. Common subtypes include mycosis fungoides (the most prevalent, often starting as scaly patches) and Sézary syndrome (more aggressive, involving widespread redness and circulating cancer cells). Rarer types/variants of CTCL:

• Extranodal NK/T-cell lymphoma
• Lymphomatoid papulosis
• Primary cutaneous anaplastic large cell lymphoma
• Primary cutaneous gamma/delta T-cell lymphoma
• Subcutaneous panniculitis-like T-cell lymphoma

CTCL affects about 3,000 new patients annually in the U.S., primarily adults over 50, though Dupixent-related cases appear in younger individuals.

Symptoms include red, itchy patches; thickened plaques; tumors; or generalized erythroderma. Early detection is crucial, but misdiagnosis as eczema is common, especially in patients with long-standing dermatitis.

Research Reports Link CTCL with use of Dupilumab

Multiple research reports link the use of dupilumab, the active ingredient in Dupixent, with CTCL, including a study in the Journal of the American Academy of Dermatology. This study reported an increased risk of CTCL found in a cohort of atopic dermatitis patients who used dupilumab.  It also noted that, “The increased risk persisted after exclusion of prior disease-modifying antirheumatic drug use. Risk was not increased for other cutaneous or lymphoid malignancies.” For links to this and other studies, reports, analyses, and findings, please see the Sources section at the bottom of this page.

The Growing Wave of Lawsuits Tied to CTCL Injuries

Dupixent lawsuits are product liability claims centered on failure-to-warn allegations against Sanofi and Regeneron. Filed in federal and state courts since early 2025, these cases contend that the companies knew or should have known about the CTCL risk-based on post-marketing data but that they prioritized sales—over $10 billion annually—over safety updates. A landmark filing in October 2025 includes a wrongful death claim where a patient developed peripheral T-cell lymphoma (a CTCL subtype) after Dupixent injections for eczema, leading to rapid decline and death within months of diagnosis.

Key elements of these lawsuits include:

• Delayed Diagnosis: Plaintiffs claim symptoms were dismissed as treatment-resistant eczema, delaying biopsies.
• Worsening Progression: Some allege Dupixent accelerated undiagnosed CTCL, with biopsies showing increased cell density and lichenoid patterns post-treatment.
• Compensation Sought: Damages cover medical costs, lost income, pain and suffering, and punitive awards for alleged negligence.

Litigation is in early stages, with the courts considering multidistrict litigation (MDL) consolidation.

Dupixent Lawyers

If you or a loved one used Dupixent and developed cutaneous T-cell lymphoma (CTCL), contact us to discuss filing a Dupixent lawsuit. The consultation is free. You pay nothing unless you win your case and receive compensation.